Update on antiplatelet therapy for stroke prevention

Ralph L. Sacco, Mitchell S. Elkind

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.

Original languageEnglish (US)
Pages (from-to)1579-1582
Number of pages4
JournalArchives of internal medicine
Issue number11
StatePublished - Jun 12 2000
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Update on antiplatelet therapy for stroke prevention'. Together they form a unique fingerprint.

Cite this